| Date | Title | Description |
| 01.08.2025 | The Melanoma Research Foundation Launches its Annual Philadelphia 5K Fundraiser with a Goal of $110,000 in Support of its Mission | The Melanoma Research Foundation (MRF) is thrilled to announce one of the next events in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we wi... |
| 26.04.2025 | Granite Bio: A New Force in Immunology with $100 Million Backing | Granite Bio has burst onto the scene, armed with $100 million in funding. This clinical-stage immunology company is not just another player; it’s a potential game-changer. With a focus on autoimmune diseases, Granite Bio is targeting the ro... |
| 25.04.2025 | Granite Bio: Immunology Company Debuts With $100 Million In Funding | Granite Bio, a clinical-stage immunology company, announced it has emerged from stealth with $100 million in funding. This includes a $30 million Series A led by founding investors Versant Ventures and Novartis Venture Fund and a $70 millio... |
| 05.02.2025 | SailPoint's IPO: A Second Chance at the Public Market | SailPoint Technologies Inc. is making waves again. The identity security company is gearing up for its second initial public offering (IPO), aiming to raise $1.05 billion. This move comes after a rollercoaster ride through the public and pr... |
| 02.02.2025 | 3 Niche Healthcare Stocks Tackling Rare Diseases The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid evolution of medical technolog... | The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid evolution of medical technologies. Hence, investors might consider investing in niche healthcare stocks, Immunocore Hol... |
| 11.11.2024 | 3 Fast-Growing Stocks Analysts See Doubling in Price Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launche... |
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly,... |
| 05.09.2024 | Immunocore Selects Genedata to Scale Up Discovery of Novel TCR Therapeutics | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
BASEL, Switzerland, Sept. 5, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading pr... |
| 27.03.2024 | Meet the companies that raised the top 7 UK funding rounds in Q1 2024; 6 of them hiring right now | Read this article in:
Funding is the backbone for the remarkable growth of startups in many countries, including the UK. The generous investment received by UK startups from venture capitalists plays a massive role in the country’s advancem... |
| 05.03.2024 | Immunocore presented two posters at CROI 2024 | - |
| 01.03.2024 | Oncobit joins forces with Immunocore | Oncobit is a medtech spin-off from the University Hospital of Zurich, that has developed a scalable and data-driven cancer monitoring platform based on a unique combination of proprietary digital PCR assays and software. Its products aim to... |
| 02.12.2022 | Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors | Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
Gamma delta TCRs offer potential to address large number of patients without HLA restrictions
Agreement combines Gadeta's gamma delta tar... |
| 09.11.2022 | Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America | With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therap... |
| 18.07.2022 | Immunocore Announces $140 Million Private Placement Financing | PRESS RELEASE
Immunocore Announces $140 Million Private Placement Financing
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 18 July 2022) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a co... |
| 08.06.2022 | Medison Pharma Announces the Approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK® (tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma | KIMMTRAK has been approved in Canada and Australia for the treatment of an aggressive form of ocular melanoma and follows approval in the United States and the European Union
PETACH TIKVAH, Israel, June 8, 2022 /PRNewswire/ -- Today, Mediso... |
| 23.05.2022 | Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand | The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering
PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ -- Medison Pharma ("Medison")... |
| 11.08.2021 | Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update | Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 25.03.2021 | Immunocore Provides Business Update and Reports Full Year 2020 Financial Results | Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and auto... |
| 09.02.2021 | Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297 | Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 09.02.2021 | Immunocore Announces Closing of $312.1 Million Financing | Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 19.01.2021 | The silent warriors of Jan 2021: 10 UK tech startups whose funding went under the radar | Despite the COVID-19 pandemic crisis that forced the whole world to come to a grinding halt, the London tech firms have raised £7.6B VC funding in 2020 and it hasn’t stopped with 2020 as the investments are still going on a full swing as we... |
| 13.01.2021 | Immunocore Closes $75M Series C Funding Round | Immunocore, a Milton Park, Oxfordshire, U.K.-based late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cance... |
| 11.01.2021 | Immunocore announces closing of $75.0 Million Series C round | Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease,... |
| 11.01.2021 | Immunocore Limited announced that it has received $75 million in funding from BlackRock, Inc. | Immunocore Limited announced that it has received $75 million in its series C round of funding led by existing investor on January 11, 2021. The transaction included participation from existing investors and new investor funds and accounts ... |
| 18.03.2020 | Immunocore Raises $130M in Series B Financing | Immunocore, a Milton Park, Oxfordshire, UK-based clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of medicines for cancer, infection and autoimmune disease, completed an over $130m S... |
| 06.03.2020 | Clinical-Stage T Cell Receptor Biotech Company Immunocore Raises Over $130 Million | Immunocore, a clinical-stage T cell receptor biotechnology company, announced it raised over $130 million
Immunocore — a clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transform... |
| 02.03.2020 | Immunocore raises $130M to fund pivotal cancer program | Immunocore has raised a $130 million (€117 million) series B round, ending its long wait for fresh funding. The British biotech made waves in 2015 with a $320 million series A but reportedly had to slash the near-unicorn valuation it achiev... |
| 02.03.2020 | Immunocore raises $130M to fund pivotal cancer program | Immunocore has raised a $130 million (€117 million) series B round, ending its long wait for fresh funding. The British biotech made waves in 2015 with a $320 million series A but reportedly had to slash the near-unicorn valuation it achiev... |
| 02.03.2020 | Immunocore Secures $130 Million Series B Financing | Immunocore, a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today annou... |
| 02.03.2020 | Immunocore Secures $130 Million Series B Financing | Led by General Atlantic, funding will help aid the expansion of novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic |
| 16.07.2015 | UPDATED: T-cell pioneer Immunocore scores a record-breaking $320M round | Immunocore CEO Eliot Forster
In another example of the big bets being made on reengineering T cells to attack cancer, Oxford, U.K.-based Immunocore has come up with a monster $320 million venture round designed to push the pipeline well pas... |
| 16.07.2015 | Immunocore Closes US$320M Financing Round | Immunocore Limited, an Oxon, UK-based biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, completed a US$320m (GBP£205m) private financing round.
Back... |
| 16.07.2015 | Lilly partner Immunocore raises record $320 million | - |
| 16.07.2015 | Daily funding roundup - July 16, 2015 | Immunocore raised $320M; Zeta Interactive closed $125M; Flipagram landed $70M
Private equity firm iTech Capital has invested $3 million in TradingView, a social fintech platform that unites traders and investors from around the world. iTech... |
| 16.04.2015 | Medmmune & Immunocore collaborate to conduct immuno-oncology combination trials in melanoma | Medmmune & Immunocore collaborate to conduct immuno-oncology combination trials in melanoma
16-04-2015
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a collaboration to co... |
| 09.01.2014 | MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies | MedImmune and Immunocore enter immunotherapy agreement to develop novel cancer therapies
09-01-2014
AstraZeneca has announced that MedImmune, its global biologics research and development arm, has entered into an oncology research collabora... |
